Positive phase II trial data with novel anti-PCSK9 agent
EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.
This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.
Prof. Evan Stein, LIB Therapeutics and Metabolic & Atherosclerosis Research Center, Cincinnati, OH, USA
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.